Module 1: Photosafety Evaluation: Why, When, and How to Conduct?
Recorded On: 02/27/2025
Phototoxic properties of systemically applied pharmaceuticals may be the cause of serious adverse drug reactions. Despite being clinically manageable in principle, they can limit the use of a drug depending on the indication. Protective measures against sunlight can be applied very reasonably during a few days but may not be practicable for chronic treatments. Thus, both patients and health authorities are unlikely to accept a relevant photosensitization risk in such situations.
Since the global adoption of ICH S10 “Photosafety Evaluation of Pharmaceuticals” in 2013, both the industry and CROs have gained significant experience in conducting risk assessment for phototoxicity potentials for pharmaceuticals. However, it still requires an individual project toxicologist to consider various aspects of a pharmaceutical program to have a staged and integrated analysis of the risk.
Also, special experience and equipment are needed to conduct compliant studies, for which most of the toxicologists lack hands-on experience. This module focuses on providing details on the in vitro and in vivo studies as part of a tiered testing strategy and providing the scenarios and principles to guide an integrated human risk assessment.
Daniel Bauer, PhD
Director of Preclinical Safety
Novartis
Dr. Daniel Bauer is Director of Preclinical Safety at Novartis in Basel, Switzerland. He is a trained chemist and a board-certified toxicologist with over 20 years of experience in the pharmaceutical industry. Dr. Bauer began his career at Novartis as a lab head in molecular and cellular toxicology, later specializing in photosafety evaluation with a focus on tiered testing strategies from in vitro to in vivo to clinical translation.
As a study director and monitor, Dr. Bauer has contributed to numerous in vitro safety screening studies, including phototoxicity and genetic toxicity, during candidate selection. He has also supervised in vitro phototoxicity studies under GLP. Currently, he serves as Global Expert in Photosafety, overseeing all photosafety activities at Novartis.
For EFPIA, Dr. Bauer was a member of the ICH S10 Expert Working Group representing the European pharmaceutical industry. He is currently the chair of the EFPIA Photosafety Working Group, where he facilitates industry-wide knowledge exchange and new initiatives.
In addition, Dr. Bauer acts as a project toxicologist, working on topical and oral FIH projects in dermatology and oncology indications.